aldr to double again from here
next week in Lisbon, Portugal. However, it is very hard to find their presentation on the abstracts. there are over 690s of them
you do not know what you are talking about. Technically this stock is a sell for the shortterm, but the drug will be a blockbuster. Smart money including myself already sold above 100 when this thing failed to recover. Do you research and talk.
commodity prices will always reverse. It is when not if ever.
they know that csco will win big and anet will have to pay all the profits to them.
ALL in kids has a 91 percent cure rate or remission rate with the current treatment. annually there are 6000 cases in us, and there are 1600 adults. adults have a 40% survival rate and long term cure rate . With Juno's treatment it is increased to 59% so far in survival rate. However, there are some deaths with treatment. Also 80-90 % of adult ALL patients achieve remission. Juno's treatment has its place, but it is not a drastic change that leads to a cure rate of 91%. It is far from it. I think that Juno may come under pressure this week.
I doubt that competitions can unseat EW's leading position. But Wall Street sold on any uncertainty. EW's stock will have lots of volatility for the next 3 quarters to redeem itself. Earnings and procedures volumes will have to prove that it is staying on top. This should be only temporary setback for longs.
aldr's drugs have equal or higher potentials to rcpt's drugs
this is a must-own like Juno. Multiple myeloma is a huge market opportunity for them. They should start trials at OSU/Cleveland Clinic soon.
I am a physician.
1. PFE did not do anything because they have lipitor and crestor is killing them. They underestimate the size of the market.
2. This drug is moving quickly through trials. Read the management's comments.
3. Amgn and REGN are developing the injectables for similar indications. But they are injectables.
4. Safety data does way beyond the time frame of 12 weeks
5. What dosing does this analyst know? you find the appropriate dosing at phase 1 and 2. No problem with the appropriate doses.
6. There will be post market study on the side effects. Phase 3 will take time well into next year. What are you talking about?
7-8. weak interactions? means low side effect profile. It already proved the safety and efficacy on phase 2b.
9-10. No muscle aches (myalgia) combined with Zetia. Crestor and Lipitor causes Liver enzymes (LFTs) to rise. It has non of the main side effects of Crestor and Lipitor. Lipitor was a 10 billion dollar a year drug and Crestor now 7-8 billions a year.
11-12. BS totally. You don't combine with high dose statins yet. you use it with Zetia. It is not what it is indicated for.
13-14. Yes there is no strong pipeline with multiple drugs. However, once the phase 3 is underway with update readings this company will be bought out at 5 billions or more. PCYC is one drug wonder cothat was bought out at 21 billions plus. Peak sales 4-5 billions or more for ECT-1002. Gild surged 100 billions more with sovaldi as well as immunex with enbrel. all one drug wonder companies.
In summary this guy is full of BS and intend to benefit from shorting. Some clowns published a bs thesis on isis when it was at 35 last year. It caused a drop from 36 to 32 but it quickly recovered. There are no new brand cholesterol drugs coming on the market any time soon. So you figure espr fills the void with the indications for statin intolerant patients. Do your due diligence. Psychology may be spooked for now but truth will prevail.